Jason Hoitt
Known title: Chief Patient OfficerCIK: 0001762572
Associated companies
Transaction History
| STOK | ▼ Sell | Open Market | 1,762 | $55K | 3/18/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 139 | $4K | 3/18/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 30 | $986 | 3/18/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 1,033 | $34K | 3/17/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 748 | $25K | 3/17/2026 | View on chart |
| STOK | ▲ Buy | Option Exercise | 10,000 | $0 | 3/15/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting
Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting. Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.